Signison

Signison is a biotechnology company developing a proprietary platform for ultrasound-mediated drug delivery to improve the targeting and efficacy of various therapeutic classes. The company's technology leverages ultrasound energy to facilitate the localized release and cellular uptake of drugs, including small molecules and nucleic acids, directly within diseased tissues such as solid tumors. By enhancing local concentration and reducing systemic exposure, Signison aims to overcome traditional barriers in drug delivery and improve patient outcomes in oncology and other therapeutic areas. The company's approach is based on pioneering research in molecular imaging and therapeutic ultrasound conducted by its founders.